Scientific Literature
You are now entering the scientifc library portion of our web site. The information contained in this section is intended to provide you with a balanced overview of information relating to the safety and efficacy of Wellmune WGP, the active ingredient in Immune Health Basics.
Wellmune WGP is a gluco polysaccharride derived from a proprietary strain of yeast. Its molecular structure is unique and results in biological activity that cannot be replicated by other immune health products. These articles are intended for general education purposes. This section does not constitute labeling, endorsements or advertisements and should not be interpreted as recommending how to treat any particular diseases or health-related conditions.
Biothera 's research program has generated the following studies, which include both clinical and preclinical research. Follow the links below for the official abstracts for each study.
December 2010
A randomised controlled trial to assess the ability of yeast-derived 1,3/1,6 glucopolysaccharide to reduce upper respiratory tract infection symptoms.
Presentation: The British Society of Immunology. Publication pending
April 2010
Presentation: Experimental Biology, 2010. Publication pending.
February 2010
Beta 1,3/1,6 Glucan Decreases Upper Respiratory Tract Infection Symptoms and Improves Psychological Well-being in Moderate to Highly-Stressed Subjects.
Agro Food Industry Hi-Tech (2010) 21:21-24.
December 2009
Effect of Beta 1, 3/1, 6 Glucan on Upper Respiratory Tract Infection Symptoms and Mood State in Marathon Athletes.
Journal of Sports Science and Medicine (2009). 8:509-515.
July 2009
Randomized Phase II Clinical Trials of Wellmune WGP® for Immune Support During Cold and Flu Season.
The Journal of Applied Research (2009) 9:20-42.
May 2008
Presentation: American College of Sports Medicine. Publication pending.
